KLK3 and posterior cortical atrophy: As the investigated meth-ctDNA markers partially show great potential for accurate, minimally-invasive diagnosis of mCRPC and survival prognostication, their applicability for systemic therapy response prediction, as ICEs for outcome surrogacy and their incremental value for disease monitoring in PSA-low advanced PCa should be investigated in future prospective trials.